Izraēla - ivrits - Ministry of Health

קלינטיקה בע"מ - כלל האוכלוסיה - בדיקות דופק

Izraēla - ivrits - Ministry of Health

abic marketing ltd, israel - levocarnitine - תמיסה - levocarnitine 30 % - levocarnitine - levocarnitine - systemic and myopathic carnitine deficiency.

Izraēla - ivrits - Ministry of Health

devries & co. ltd - betamethasone - טבליה - betamethasone 0.5 mg - betamethasone - betamethasone - diseases responsive to oral glucocorticosteroid therapy.

Izraēla - ivrits - Ministry of Health

novartis israel ltd - ribociclib as succinate - טבליות מצופות פילם - ribociclib as succinate 200 mg - ribociclib

Izraēla - ivrits - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

Izraēla - ivrits - Ministry of Health

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

Izraēla - ivrits - Ministry of Health

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

Izraēla - ivrits - Ministry of Health

unipharm ltd - valsartan 40 mg - film coated tablets - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Izraēla - ivrits - Ministry of Health

unipharm ltd, israel - valsartan - טבליה - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Izraēla - ivrits - Ministry of Health

taro international ltd, israel - cyproterone acetate; ethinylestradiol - טבליה - ethinylestradiol 0.035 mg; cyproterone acetate 2 mg - for the treatment of signs of androgenization in women such as pronounced forms of acne, androgenic alopecia and mild forms of hirsutism.